argenx SE (0QW0.IL)
- Previous Close
505.20 - Open
497.90 - Bid 475.80 x --
- Ask 525.80 x --
- Day's Range
497.90 - 508.80 - 52 Week Range
348.70 - 656.80 - Volume
5,014 - Avg. Volume
16,485 - Market Cap (intraday)
29.465B - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
-- - EPS (TTM)
-6.55 - Earnings Date Jul 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
www.argenx.comRecent News: 0QW0.IL
View MorePerformance Overview: 0QW0.IL
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0QW0.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0QW0.IL
View MoreValuation Measures
Market Cap
30.88B
Enterprise Value
27.98B
Trailing P/E
35.45
Forward P/E
59.52
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.05
Price/Book (mrq)
6.46
Enterprise Value/Revenue
12.48
Enterprise Value/EBITDA
88.23
Financial Highlights
Profitability and Income Statement
Profit Margin
-47.52%
Return on Assets (ttm)
-10.29%
Return on Equity (ttm)
-13.62%
Revenue (ttm)
835.26M
Net Income Avi to Common (ttm)
-396.9M
Diluted EPS (ttm)
-6.55
Balance Sheet and Cash Flow
Total Cash (mrq)
2B
Total Debt/Equity (mrq)
0.39%
Levered Free Cash Flow (ttm)
-458.4M